Therapeutic Drug Monitoring of Venlafaxine and Impact of Age, Gender, BMI, and Diagnosis

[1]Alventa SPC. (https://www.adc.sk/databazy/produkty/spc/alventa-75-mg-304880.html). Revised October 2019. Accessed December 20, 2019.Alventa SPC(https://www.adc.sk/databazy/produkty/spc/alventa-75-mg-304880.html). Revised October 2019. Accessed December 20, 2019.Search in Google Scholar

[2]American Psychiatric Association (APA). DSM-5. (https://www.psychiatry.org/psychiatrists/practice/dsm). Revised October 2018. Accessed January 24, 2020.American Psychiatric Association (APA)DSM-5(https://www.psychiatry.org/psychiatrists/practice/dsm). Revised October 2018. Accessed January 24, 2020.Search in Google Scholar

[3]Cai L, Xu L, Wei L, Chen W. Relationship of Mean Platelet Volume To MDD: A Retrospective Study. Shanghai Arch Psychiatry. 2017;29(1):21–29.CaiLXuLWeiLChenWRelationship of Mean Platelet Volume To MDD: A Retrospective StudyShanghai Arch Psychiatry20172912129Search in Google Scholar

[4]Hansen MR, Kuhlmann IB, Pottegård A, Damkier P. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships. Basic Clin Pharmacol Toxicol. 2017;121(4):298–302.HansenMRKuhlmannIBPottegårdADamkierPTherapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration RelationshipsBasic Clin Pharmacol Toxicol2017121429830210.1111/bcpt.1279628397349Search in Google Scholar

[5]Hiemke C. Clinical utility of drug measurements and pharmacokinetics – therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol. 2008;64:159–166.HiemkeCClinical utility of drug measurements and pharmacokinetics – therapeutic drug monitoring in psychiatryEur J Clin Pharmacol20086415916610.1007/s00228-007-0430-118196227Search in Google Scholar

[6]Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62.HiemkeCBergemannNClementHWConsensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017Pharmacopsychiatry2018511–0296210.1055/s-0043-11649228910830Search in Google Scholar

[7]Kertys M, Krivosova M, Ondrejka I, Hrtanek I, Tonhajzerova I, Mokry J. Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC–MS/MS using one-step sample preparation procedure. J Pharm Biomed Anal. 2020;181:113098.KertysMKrivosovaMOndrejkaIHrtanekITonhajzerovaIMokryJSimultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC–MS/MS using one-step sample preparation procedureJ Pharm Biomed Anal202018111309810.1016/j.jpba.2020.11309831978643Search in Google Scholar

[8]Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62(4):321–6.KloiberSIsingMReppermundSOverweight and obesity affect treatment response in major depressionBiol Psychiatry2007624321610.1016/j.biopsych.2006.10.00117241618Search in Google Scholar

[9]Luppa M, Sikorski C, Luck T, et al. Age- and gender-specific prevalence of depression in latest-life--systematic review and meta-analysis. J Affect Disord. 2012;136(3):212–21.LuppaMSikorskiCLuckTAge- and gender-specific prevalence of depression in latest-life--systematic review and meta-analysisJ Affect Disord201213632122110.1016/j.jad.2010.11.03321194754Search in Google Scholar

[10]Marazziti D, Baroni S, Picchetti M, et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr. 2013;18(3):118–27.MarazzitiDBaroniSPicchettiMPharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sexCNS Spectr20131831182710.1017/S109285291200101023374978Search in Google Scholar

[11]National health information center (NHIC). Prescription Drug Use in Slovak Republic in 2018. (http://www.nczisk.sk/Statisticke_vystupy/Tematicke_statisticke_vystupy/TOP-50-liekov/Pages/Spotreba-humannych-liekov-v-slovenskej-republike.aspx). Revised December 2019. Accessed January 24, 2020.National health information center (NHIC)Prescription Drug Use in Slovak Republic in 2018(http://www.nczisk.sk/Statisticke_vystupy/Tematicke_statisticke_vystupy/TOP-50-liekov/Pages/Spotreba-humannych-liekov-v-slovenskej-republike.aspx). Revised December 2019. Accessed January 24, 2020.Search in Google Scholar

[12]Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41(2):149–56.OttonSVBallSECheungSWInabaTRudolphRLSellersEMVenlafaxine oxidation in vitro is catalysed by CYP2D6Br J Clin Pharmacol19964121495610.1111/j.1365-2125.1996.tb00173.x8838442Search in Google Scholar

[13]Paulzen M, Groppe S, Tauber SC, Veselinovic T, Hiemke C, Gründer G. Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. J Clin Psychiatry. 2015;76(1):25–31.PaulzenMGroppeSTauberSCVeselinovicTHiemkeCGründerGVenlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluidJ Clin Psychiatry2015761253110.4088/JCP.13m0892125188033Search in Google Scholar

[14]Reis M, Aamo T, Spigset O, Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31(1):42–56.ReisMAamoTSpigsetOAhlnerJSerum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring databaseTher Drug Monit2009311425610.1097/FTD.0b013e31819114ea19077925Search in Google Scholar

[15]Reyes-Barron C, Tonarelli S, Delozier A, et al. Pharmacogenetics of antidepressants, a review of significant genetic variants in different populations. Clin. Depress. 2016;2(1):109.Reyes-BarronCTonarelliSDelozierAPharmacogenetics of antidepressants, a review of significant genetic variants in different populationsClin. Depress201621109Search in Google Scholar

[16]Sigurdsson HP, Hefner G, Ben-omar N, et al. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. J Neural Transm (Vienna). 2015;122(5):721–9.SigurdssonHPHefnerGBen-omarNSteady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMIJ Neural Transm (Vienna)20151225721910.1007/s00702-014-1317-9Search in Google Scholar

[17]State Institute for Drug Control (SIDC). Database of medicaments. (https://www.sukl.sk/en/servis/search/searching-on-the-database-of-medicinal-products?page_id=410&lie_nazov=&atc_nazov=venlafax%C3%ADn&lie_kod=&atc_kod=&lie_rc=&drz_kod=). Revised January 2020. Accessed January 24, 2020.State Institute for Drug Control (SIDC)Database of medicaments(https://www.sukl.sk/en/servis/search/searching-on-the-database-of-medicinal-products?page_id=410&lie_nazov=&atc_nazov=venlafax%C3%ADn&lie_kod=&atc_kod=&lie_rc=&drz_kod=). Revised January 2020. Accessed January 24, 2020.Search in Google Scholar

[18]Tirona RG, Kim RB. Introduction to Clinical Pharmacology. In: Robertson D, Williams GH. Clinical and Translational Science, 2^nd ed. Academic Press; 2017.TironaRGKimRBIntroduction to Clinical PharmacologyIn:RobertsonDWilliamsGHClinical and Translational Science2nd ed.Academic Press201710.1016/B978-0-12-802101-9.00020-XSearch in Google Scholar

[19]Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843–53.TurnheimKWhen drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderlyExp Gerontol20033888435310.1016/S0531-5565(03)00133-5Search in Google Scholar

[20]Unterecker S, Hiemke C, Greiner C, et al. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry. 2012;45(6):229–35.UntereckerSHiemkeCGreinerCThe effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditionsPharmacopsychiatry20124562293510.1055/s-0031-130136622426847Search in Google Scholar

[21]World Health Organisation (WHO). Depression and Other Common Mental Disorders. Global Health Estimates. (https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1&isAllowed=y). 2017. Accessed January 24, 2020.World Health Organisation (WHO)Depression and Other Common Mental Disorders. Global Health Estimates(https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1&isAllowed=y). 2017. Accessed January 24, 2020.Search in Google Scholar

[22]World Health Organisation (WHO). Depression. (https://www.who.int/news-room/fact-sheets/detail/depression). Revised December 2019. Accessed January 23, 2020.World Health Organisation (WHO)Depression(https://www.who.int/news-room/fact-sheets/detail/depression). Revised December 2019. Accessed January 23, 2020.Search in Google Scholar